Meet the new porfolio Company - Ophiomics
On 16 December last Ophiomics concluiu uma ronda de financiamento integralmente coberta por fundos geridos pela sociedade de capital de risco BlueCrow.
The investment of the BlueCrow aims to develop the commercial aspect of HepatoPredictIt is designed to be marketed in at least five countries in the European Union, two countries in the Middle East and to enhance the clinical validation of the product.
In parallel a strategy is defined to complete the proof of concept study and submission for publication of the HepatoDetectas well as initiating the design and consequent industrialisation of the product.
The second phase of the strategic plan focuses on expanding the HepatoPredict to the United States, Asia and South America, and marketing to more than ten countries in the European Union and four countries in the Middle East.
Founded by José Leal and Joana Vaz, experts in Bioinformatics and Genomics, respectively, the Ophiomics is based in Lisbon, Portugal, in the LISPOLIS incubator, close to several small and large companies focusing on human health technologies.
The Ophiomics is a Portuguese biotechnology company specialising in precision medicine services in the oncology area, and develops new methods of analysis and testing, seeking to help doctors diagnose each patient's disease on a case-by-case basis.
In other words, it develops new precision medicine solutions, specifically, in vitro diagnostic medical devices in the field of oncology, integrating genomics and bioinformatics as pillars of R&D.
The HepatoPredict, is an in vitro diagnostic medical device that uses molecular biology and artificial intelligence to assess whether liver cancer patients can receive a liver transplant for cure. In practical terms, it is a laboratory test in which a tumour is biopsied and allows the team of doctors to choose the appropriate therapy for the patient.
The HepatoDetect é uma biópsia líquida onde a integração de variáveis moleculares através de inteligência artificial permite fazer um rastreio de doentes com cirrose para a deteção precoce do cancro do fígado. É um teste de sangue que permite aumentar significativamente, de forma custo efectiva, a taxa de deteção precoce de cancro do fígado numa população de risco.
To José Leal, "This investment will enable the commercial development of the HepatoPredict to the global market, while also enabling the development of other innovative molecular tests to help reduce the scourge of early death from liver and other gastrointestinal tract cancers. "
Bernardo Empis Meira, Partner da BlueCrow, acrescenta "we share the same goal of contributing to solutions that save lives and have a relevant impact on increasing the quality of life of the Society. "
